Development of nanoparticle-based Toll-like receptor agonists for respiratory immunotherapy
Open Access
- 7 January 2026
- journal article
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 102-130
Abstract
Respiratory diseases are global health challenges demanding innovative immunotherapy solutions. Toll-like receptors (TLRs) play a crucial role in immune responses, making them attractive therapeutic targets. This review examines nanoparticle-based Toll-like receptor agonists as a promising approach for respiratory immunotherapy. Nanoparticles offer targeted drug delivery and sustained release, ideal for enhancing TLR agonist efficacy. This article explores TLRs' role in immunomodulation, nanoparticle applications, design considerations, preclinical efficacy, safety assessments, challenges, and future prospects. Promising results from animal studies suggest enhanced immunological responses and reduced inflammation compared to conventional treatments. Safety concerns are addressed with insights from toxicity studies. Challenges include regulatory hurdles and biocompatibility, with strategies proposed for optimization. Nanoparticle-based TLR agonists hold great potential to transform respiratory disease treatment, warranting further research and collaboration for successful clinical translation.Keywords
This publication has 80 references indexed in Scilit:
- Pulmonary Arterial HypertensionProceedings of the American Thoracic Society, 2006
- How Toll-like receptors signal: what we know and what we don’t knowCurrent Opinion in Immunology, 2006
- Long-Term Clearance Kinetics of Inhaled Ultrafine Insoluble Iridium Particles from the Rat Lung, Including Transient Translocation into Secondary OrgansInhalation Toxicology, 2004
- Chitosan IFN-γ-pDNA Nanoparticle (CIN) Therapy for Allergic AsthmaGenetic Vaccines and Therapy, 2003
- Toll-Like Receptor Signaling PathwaysScience, 2003
- Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucusGene Therapy, 2002
- The Dorsoventral Regulatory Gene Cassette spätzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila AdultsCell, 1996
- Approaching the Asymptote? Evolution and Revolution in ImmunologyCold Spring Harbor Symposia on Quantitative Biology, 1989
- The Toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane proteinCell, 1988
- Deposition and clearance of inhaled particles.Environmental Health Perspectives, 1984